


**Product Name** : Domatinostat  
**Cat. No.** : PC-73192  
**CAS No.** : 910462-43-0  
**Molecular Formula** : C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S  
**Molecular Weight** : 447.51  
**Target** : HDAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

Domatinostat (4SC-202) is a selective **class I HDAC** inhibitor with IC<sub>50</sub> of 1.20/1.12/0.57 μM for HDAC1/2/3, respectively. Domatinostat (4SC-202) weakly inhibits Class III (HDAC11, IC<sub>50</sub>=9.7 μM), does not inhibit HDAC4/6/7/8/9 (IC<sub>50</sub>>50 μM). Domatinostat (4SC-202) potently inhibited survival and proliferation of primary human colon cancer cells and established CRC lines (HT-29, HCT-116, HT-15, and DLD-1).

4SC-202 provoked apoptosis activation, induced dramatic G<sub>2</sub>-M arrest in CRC cells. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to potently inhibit human HCC cells.

4SC-202 induces hyperacetylation of histone H3 in a dose dependent manner with a cellular potency EC<sub>50</sub> of 1.1 μM.

4SC-202 shows a broad anti-proliferative/cytotoxic activity towards human cancer cell lines from various indications with mean IC<sub>50</sub> of 0.7 μM.

4SC-202 showed pronounced and robust anti-tumor activity in various cancer cell lines and xenograft animal models.

## References

Fu M, et al. *Biochem Biophys Res Commun*. 2016 Mar 4;471(2):267-73.

Zhijun H, et al. *Tumour Biol*. 2016 Aug;37(8):10257-67.

Pinkerneil M, et al. *Target Oncol*. 2016 Dec;11(6):783-798.

von Tresckow B, et al. *Eur J Haematol*. 2019 Feb;102(2):163-173.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com